Grail anticipates FDA approval and insurer adoption for Galleri test
GRAL GRAIL Inc
$99.25 -5.33%
View chart & analysis → - 1Grail's market capitalization volatility of $4.46 billion is likely to continue next year.
- 2Grail management expects Galleri, a multi-cancer early detection test, to be approved in Q1 2027.
- 3The expected price range for the Galleri test is $500 to $600.
So what's the key point?
Grail's market capitalization volatility of $4.46 billion is likely to continue next year.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.